WA
ACAD icon

WFG Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

WFG Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-82
Closed -$2K – 1974
2013
Q4 		$2K Sell
82
-800
-91% -$18.9K ﹤0.01% 1941
2013
Q3 		$24K Hold
882
– – ﹤0.01% 1200
2013
Q2 		$16K Buy
+882
New +$12.1K ﹤0.01% 1281

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

WFG Advisors's ACAD Position: Q1 2014 in Review

WFG Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2014, closing a stake of 82 shares — an estimated $2K sold.

WFG Advisors first reported a position in ACAD in Q2 2013 and held it in 3 quarters. The position peaked at $24K in Q3 2013. 168 funds tracked by Wall St. Rank hold ACAD as of Q1 2014.

  • WFG Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • WFG Advisors sold 82 Acadia Pharmaceuticals shares in Q1 2014, an estimated $2K.
  • WFG Advisors first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • WFG Advisors's Acadia Pharmaceuticals position peaked at $24K in Q3 2013.
  • 168 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2014.

Based on WFG Advisors's 13F filing for Q1 2014, filed 24 Apr 2014.